These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38444394)

  • 1. Direct induction onto high-dose long-acting injectable buprenorphine: A case series.
    Naren T; Cook J; MacCartney P
    Australas Psychiatry; 2024 Jun; 32(3):238-241. PubMed ID: 38444394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
    Soyka M
    Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine.
    Naren T; Cook J; MacCartney P; Membrey D
    Drug Alcohol Rev; 2024 May; 43(4):1013-1018. PubMed ID: 38408741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products.
    Daglish MRC; Hayllar JS; McDonough M
    J Subst Use Addict Treat; 2024 Jul; 162():209348. PubMed ID: 38494054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
    Morgan JR; Schackman BR; Weinstein ZM; Walley AY; Linas BP
    Drug Alcohol Depend; 2019 Jul; 200():34-39. PubMed ID: 31082666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report.
    Schmuhl KK; Golec A; Ebersole AM
    J Adolesc Health; 2024 Jul; 75(1):200-202. PubMed ID: 38402472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and implementation of a rapid-access long-acting injectable buprenorphine clinic in metropolitan Melbourne during the COVID-19 pandemic.
    Straub A; Pastor A; Lloyd-Jones M; O'Neill H; Bonomo Y
    Drug Alcohol Rev; 2021 May; 40(4):681-682. PubMed ID: 32898928
    [No Abstract]   [Full Text] [Related]  

  • 8. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
    Shulman M; Wai JM; Nunes EV
    CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
    Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
    JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 11. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
    Vidyasagar N; Bunting SR; Arora VM; Ari M
    JAMA; 2024 Feb; 331(6):524-526. PubMed ID: 38236586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M; Groß G
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Dose Buprenorphine Initiation in the Management of Opioid Use Disorder in Pregnancy.
    Berry M; Kiefer MK; Hinely KA; Bowden H; Jordan A; Vilensky M; Rood KM
    Obstet Gynecol; 2024 Jun; 143(6):815-818. PubMed ID: 38574367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
    Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F
    Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis.
    Neale J; Parkin S; Strang J
    Addiction; 2023 Jul; 118(7):1329-1339. PubMed ID: 36808168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
    Samples H; Williams AR; Olfson M; Crystal S
    J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.
    Parkin S; Neale J; Strang J
    Int J Drug Policy; 2023 Dec; 122():104221. PubMed ID: 37865052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
    Azar P; Schneiderman H; Barron H; Wong JSH; Meyer M; Newman-Azar D; Narimani M; Ignaszewski MJ; Mathew N; Mullen R; Krausz RM; Maharaj AR
    Addict Sci Clin Pract; 2024 Jun; 19(1):50. PubMed ID: 38886826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.